JP2023535710A5 - - Google Patents
Info
- Publication number
- JP2023535710A5 JP2023535710A5 JP2023504184A JP2023504184A JP2023535710A5 JP 2023535710 A5 JP2023535710 A5 JP 2023535710A5 JP 2023504184 A JP2023504184 A JP 2023504184A JP 2023504184 A JP2023504184 A JP 2023504184A JP 2023535710 A5 JP2023535710 A5 JP 2023535710A5
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- pharmaceutical composition
- administration
- composition according
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2011216.5A GB202011216D0 (en) | 2020-07-20 | 2020-07-20 | Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients |
| GB2011216.5 | 2020-07-20 | ||
| GBGB2011284.3A GB202011284D0 (en) | 2020-07-21 | 2020-07-21 | Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients |
| GB2011284.3 | 2020-07-21 | ||
| GBGB2106014.0A GB202106014D0 (en) | 2021-04-27 | 2021-04-27 | Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients |
| GB2106014.0 | 2021-04-27 | ||
| PCT/GB2021/051853 WO2022018422A1 (en) | 2020-07-20 | 2021-07-19 | Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535710A JP2023535710A (ja) | 2023-08-21 |
| JP2023535710A5 true JP2023535710A5 (enExample) | 2024-07-26 |
| JP7850132B2 JP7850132B2 (ja) | 2026-04-22 |
Family
ID=77168292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504184A Active JP7850132B2 (ja) | 2020-07-20 | 2021-07-19 | ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230338475A1 (enExample) |
| EP (1) | EP4181944A1 (enExample) |
| JP (1) | JP7850132B2 (enExample) |
| KR (1) | KR20230041097A (enExample) |
| WO (1) | WO2022018422A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250281576A1 (en) * | 2021-01-13 | 2025-09-11 | Abion Inc. | Prophylactic administration method against respiratory virus, comprising administering interferon-beta to potential respiratory virus-infected subject |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030609A (en) | 1995-05-19 | 2000-02-29 | Case Western Reserve University | Method and composition for treating paramyxovirus |
| CN1535724B (zh) | 2003-04-23 | 2012-09-05 | 北京金迪克生物技术研究所 | 重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途 |
| GB0405634D0 (en) | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
| CN1927389B (zh) | 2004-09-10 | 2012-11-14 | 北京金迪克生物技术研究所 | 含有人干扰素的药物组合物在制备预防或/和治疗呼吸道病毒感染疾病药物方面的应用 |
| US7871603B2 (en) | 2007-05-18 | 2011-01-18 | Synairgen Research Limited | Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly |
| SI2544705T1 (sl) | 2010-03-12 | 2016-11-30 | Synairgen Research Limited | Interferon beta za uporabo pri zdravljenju bolezni spodnjega dihalnega trakta, povzročene z influenco |
| JP7642536B2 (ja) * | 2018-11-15 | 2025-03-10 | ブルーウィロー バイオロジクス、インコーポレイテッド | 強化された透過性を有するナノエマルジョン組成物 |
| WO2021191456A1 (en) * | 2020-03-27 | 2021-09-30 | Vectura Limited | Compositions for the treatment of a respiratory condition |
| US20210299226A1 (en) * | 2020-03-31 | 2021-09-30 | Claresa Levetan | Method of treating and preventing coronaviruses with low dosage interferon beta-1a as a th17 inhibitor |
-
2021
- 2021-07-19 US US18/016,964 patent/US20230338475A1/en active Pending
- 2021-07-19 KR KR1020237005777A patent/KR20230041097A/ko active Pending
- 2021-07-19 WO PCT/GB2021/051853 patent/WO2022018422A1/en not_active Ceased
- 2021-07-19 EP EP21749262.8A patent/EP4181944A1/en active Pending
- 2021-07-19 JP JP2023504184A patent/JP7850132B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526547A (ja) | 気道粘膜におけるウイルス複製を低下させるための特定の薬物のシステム、方法、及び使用 | |
| Wei et al. | The antiviral mechanisms, effects, safety and adverse effects of chloroquine. | |
| US11433080B2 (en) | Antiviral treatment | |
| JP7840570B2 (ja) | コロナウイルス感染症の処置のための方法 | |
| WO2022199049A1 (zh) | 乌司他丁在制备治疗新型冠状病毒肺炎药物中的用途 | |
| JPH10500966A (ja) | 経口吸入もしくは吹き込みにより投与する為の化合物、及び組成物 | |
| EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
| JP7850132B2 (ja) | ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ | |
| US20240009227A1 (en) | Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route | |
| US20210330753A1 (en) | Methods of treating covid-19 mediated lung damage using surfactants and natural antibodies | |
| WO2022063320A1 (zh) | 一种抑制呼吸道病毒的组合物及呼吸道病毒防治方法 | |
| US20230000884A1 (en) | Combination therapy for treating covid-19 | |
| US7871603B2 (en) | Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly | |
| RU2843523C1 (ru) | Применение композиции на основе гепарина при лечении вирусных заболеваний легких, острых и/или хронических заболеваний легких с помощью ингалятора «мягкого тумана» или небулайзера с технологией вибрирующей сетки посредством ингаляционного пути введения | |
| CN116472054A (zh) | 用于改善SARS-CoV-2感染患者的预后的吸入型干扰素-β | |
| US20230241177A1 (en) | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid | |
| Vinusha et al. | Potential drugs in SARS-CoV-2 treatment: key features and mechanisms of actions | |
| JP2026077677A (ja) | コロナウイルス感染症の処置のための方法 | |
| WO2022008024A2 (en) | Gtn (glyceryl trinitrate) solution reduced respiratory distress in covid 19 patients if given by nebulization | |
| Mookhtiar | Management of SARS-COV-2; The Missing Link?: A Critical Pharmaco-Immuno-Logical Review | |
| JP2025172919A (ja) | 潜在的な呼吸器ウイルス感染個体にインターフェロンベータを投与することを含む呼吸器ウイルスに対する予防的投与方法 | |
| Krish | A Comprehensive Review of The Impact on COVID-19 On Subglottic Stenosis. | |
| TR2023001534T2 (tr) | Bi̇r hepari̇n bi̇leşi̇mi̇ni̇n yumuşak buğu i̇nhaler veya ti̇treşi̇mli̇ elek teknoloji̇si̇ nebuli̇zer vasitasiyla i̇nhale yolla covid-19 dahi̇l vi̇ral akci̇ğer hastaliklarinin, akut ve/veya kroni̇k akci̇ğer hastaliklarinin tedavi̇si̇nde kullanimi | |
| Absar et al. | Efficacy of nebulized ipratropium bromide versus salbutamol in infants with actute bronchiolities | |
| WO2022161381A1 (zh) | 血管内皮抑制素在治疗和预防冠状病毒相关疾病中的应用 |